Skip to main
  1. Stocks
  2. Eloxx Pharmaceuticals Inc
  3. Forecast
ELOX

ELOX Stock Forecast & Price Target

ELOX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eloxx Pharma is attractive fundamentally because exaluren targets a clearly validated disease mechanism—premature stop-codon readthrough—with strong precedent from aminoglycoside studies and a clean safety profile across 145 subjects in 8 early-stage trials. The most important near-term catalyst is EXACT, where 16-week topline data remain expected in mid-2027 after Phase 2a Alport data showed filtration slit density improved in all 3 patients and collagen IV rose in all 3, while cash of about $62M is guided to last into mid-2028. Longer-term, the 52-week EXPRESS design pushes ADPKD data to 1H 2029 but should strengthen the total kidney volume readout, supporting a platform that could address both the ~4.2K nonsense-mediated Alport and ~37K ADPKD patient opportunities.

Bears say

Eloxx Pharma is burdened by a weak balance sheet, with about $62M in cash, cash equivalents, and marketable securities at the end of 2Q 2026, while it is not expected to be profitable on a continuing basis until 2033, raising the odds of dilutive capital raises. The core programs also face major clinical and regulatory uncertainty: exaluren must still prove meaningful efficacy in Alport and ADPKD, and FDA has already asked for additional evidence linking filtration slit density to proteinuria, while early data showed inconsistent UPCR improvement and limited translation from preclinical findings. Added to that is commercialization risk, since delays in approval or difficulty establishing surrogate endpoints could sharply reduce value, and the early-stage, non-commercial profile leaves the company dependent on future financing and successful trial execution.

ELOX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eloxx Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

ELOX Analyst Forecast & Price Prediction

Get the latest ELOX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELOX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eloxx Pharmaceuticals Inc (ELOX) Forecast

Analysts have given ELOX a Buy based on their latest research and market trends.

According to 4 analysts, ELOX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eloxx Pharmaceuticals Inc (ELOX)


ELOX Analyst Forecast & Price Prediction

Get the latest ELOX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELOX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ELOX stock data and trends